secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENZO BIOCHEM INC (—)
CIK:        0000316253
Form:       8-K
Filed at:   2023-04-05T23:59:59+00:00
Accession:  0001213900-23-027554
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enzo Biochem enters $8M credit facility, borrows $5.5M; facility tied to clinical labs sale
--------------------------------------------------------------------------------

- $8M revolving credit facility with Gemino Healthcare Finance (SLR Healthcare ABL).
- Borrowed $5.5M at closing; proceeds for working capital and general corporate purposes.
- Interest rate: Term SOFR + 5.50% per annum; secured by substantially all U.S. assets.
- Facility expires March 29, 2024; will be prepaid upon closing of clinical labs asset sale.
- Minimum liquidity covenant: $4M (Apr 2023), $3M (May 2023), $2M thereafter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/316253/000121390023027554/0001213900-23-027554-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/316253/000121390023027554/ea176546-8k_enzobio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-027554

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer